Critical Updates: Field Safety Notices Issued from 8–12 September 2025
Important updates for clinical, quality, and regulatory teams: A series of Field Safety Notices (FSNs) were published between 8 and […]
Important updates for clinical, quality, and regulatory teams: A series of Field Safety Notices (FSNs) were published between 8 and […]
The U.S. Food and Drug Administration (FDA) announced on September 29, 2025, the authorization of Essilor Stellest eyeglass lenses. This
Olympus Corporation has announced a voluntary global recall of certain lots of its ViziShot 2 FLEX (19G) EBUS-TBNA needles. The
The U.S. Food and Drug Administration (FDA) has authorized the marketing of Essilor Stellest eyeglass lenses. This marks the first
Swissmedic has officially authorised VANFLYTA®, marking its initial regulatory approval. This announcement, dated September 30, 2025, highlights a significant development
Healthcare professionals and regulatory teams, please take note. Between 15 and 19 September 2025, a range of Field Safety Notices
On June 24, 2025, the Global Harmonization Working Party (GHWP) officially withdrew as a member of the International Medical Device
The University of Bonn has announced an upcoming clinical trial examining the effects of transcutaneous non-invasive vagus nerve stimulation (tVNS)
On October 1, 2025, Yale University announced an exciting next step in clinical research with a randomized controlled trial (RCT)
Clinical trials are underway to investigate advanced methods for assessing skin carotenoid levels using cutting-edge medical devices. Sponsored by ChinaNorm